Karyopharm Therapeutics (25K0) Stock Price & Analysis
25K0 Stock Chart & Stats
- Day’s Range
- EUR 0.67 - EUR 0.72
- 52-Week Range
- EUR 0.26 - EUR 9.25
- Previous Close
- EUR 0.73
- Volume
- 0
- Average Volume (3M)
- 814
- Market Cap
- EUR 13.44M
- Enterprise Value
- EUR 473.81M
- Total Cash (Recent Filing)
- EUR 65.11M
- Total Debt (Recent Filing)
- EUR 215.88M
- Price to Earnings (P/E)
- ―
- Beta
- 1.02
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Myelofibrosis Regulatory Progress
The myelofibrosis sNDA creates a potential expansion of selinexor’s addressable market beyond its existing uses. If accelerated or priority review succeeds and confirmatory evidence supports benefit, the program could strengthen the product franchise and materially improve future revenue durability.
Commercial Platform And Guidance
Karyopharm already has XPOVIO commercialization experience, patient support infrastructure, and coverage across community and academic settings. That platform provides a foundation for maintaining current sales and potentially launching the myelofibrosis indication efficiently if approval is obtained.
High Gross Margin And Cost Discipline
The product economics are supported by an exceptionally high gross margin, while lower R&D and SG&A indicate prioritization of higher-value programs. Although the company remains unprofitable, sustained expense discipline could improve operating leverage as revenue develops.
Bears Say
Debt Forbearance And Solvency Risk
The continuing forbearance process shows that debt compliance remains unresolved rather than representing a normal financing position. Persistent creditor negotiations can restrict strategic flexibility, increase financing costs, and leave operations dependent on additional capital or a successful restructuring.
Stressed Capital Structure
Negative equity and debt that substantially exceeds the asset base indicate a severely constrained capital structure. This reduces the company’s ability to absorb setbacks, limits internally funded investment, and increases dependence on lenders, equity issuance, or strategic transactions.
Persistent Cash Burn And Losses
Karyopharm is not yet generating enough cash to fund operations, so ongoing development and commercialization require continued liquidity access. Negative cash generation, combined with continuing losses, makes the business vulnerable if financing is delayed or if clinical and regulatory spending rises.
Karyopharm Therapeutics News
25K0 FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
What is Karyopharm Therapeutics’s market cap?
When is Karyopharm Therapeutics’s upcoming earnings report date?
How were Karyopharm Therapeutics’s earnings last quarter?
Is Karyopharm Therapeutics overvalued?
Does Karyopharm Therapeutics pay dividends?
What is Karyopharm Therapeutics’s EPS estimate?
How many shares outstanding does Karyopharm Therapeutics have?
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard A. Paulson
- Employees
- 228
- Website
- www.karyopharm.com
- Address
- 85 Wells Avenue, Newton, MA, 02459-3298, US
Karyopharm Therapeutics (25K0) Earnings & Revenues
25K0 Company Deck
25K0 Earnings Call
Earnings Call SentimentNeutral
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.
View all DE:25K0 earnings summaries25K0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 10 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 6 | 0 | 6 |
